Skip to Content

Publications Search - Abstract View

Title: HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy.
Authors: Lanoy E,  Rosenberg PS,  Fily F,  Lascaux AS,  Martinez V,  Partisani M,  Poizot-Martin I,  Rouveix E,  Engels EA,  Costagliola D,  Goedert JJ,  FHDH-ANRS CO4
Journal: Blood
Date: 2011 Jul 7
Branches: BB, IIB
PubMed ID: 21551234
PMC ID: PMC3139385
Abstract: Hodgkin lymphoma (HL) incidence with HIV infection may have increased with the introduction of combination antiretroviral therapy (cART), suggesting that immune reconstitution may contribute to some cases. We evaluated HL risk with cART during the first months of treatment. With 187 HL cases among 64 368 HIV patients in France, relative rates (RRs) and 95% confidence intervals (CIs) of HL were estimated using Poisson models for duration of cART, CD4 count, and HIV load, with and without adjustment for demographic/clinical covariates. HL risk was unrelated to cART use overall, but it was related to time intervals after cART initiation (P = .006). Risk was especially and significantly elevated in months 1-3 on cART (RR 2.95, CI 1.64-5.31), lower in months 4-6 (RR 1.63), and null with longer use (RR 1.00). CD4 count was strongly associated with HL risk (P < 10⁻⁶), with the highest HL incidence at 50-99 CD4 cells/mm³. With adjustment for CD4 count and covariates, HL risk was elevated, but not significantly (RR 1.42), in months 1-3 on cART. HIV load had no added effect. HL risk increased significantly soon after cART initiation, which was largely explained by the CD4 count. Further studies of HIV-associated HL are needed.